Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
Bodei, L.; Pepe, G.; Paganelli, G.
European Review for Medical and Pharmacological Sciences 14(4): 347-351
2010
ISSN/ISBN: 1128-3602 PMID: 20496546 Document Number: 641110
Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.
Document emailed within 1 workday
Related Documents
Papamichail, D.G.; Exadaktylou, P.E.; Chatzipavlidou, V.D. 2016: Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT) Hellenic Journal of Nuclear Medicine 19(1): 75-82Arveschoug, A.K.; Hjorthaug, K.; Rehling, M.; Højgaard, L.; Mortensen, J.; Oturai, P.S. 2009: Peptide receptor radionuclide therapy of neuroendocrine tumors Ugeskrift for Laeger 171(13): 1073
De Jong, M.; Breeman, W.A.; Bernard, H.F.; Kooij, P.P.; Slooter, G.D.; Van Eijck, C.H.; Kwekkeboom, D.J.; Valkema, R.; Mäcke, H.R.; Krenning, E.P. 1999: Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 43(4): 356-366
Pelosi, G.; Volante, M.; Papotti, M.; Sonzogni, A.; Masullo, M.; Viale, G. 2006: Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 50(4): 272-287
Parisella, M.G.; Chianelli, M.; D'Alessandria, C.; Todino, V.; Mikolajczak, R.; Papini, E.; Dierckx, R.A.; Scopinaro, F.; Signore, A. 2012: Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 56(1): 90-98
Gerasimou, G.; Moralidis, E.; Gotzamani-Psarrakou, A. 2010: Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment Hellenic Journal of Nuclear Medicine 13(2): 158-162
Otte, A.; Herrmann, R.; Mäcke, H.R.; Müller-Brand, J. 1999: Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors Praxis 88(31-32): 1263-1268
Nikou, G.C.; Lygidakis, N.J.; Toubanakis, C.; Pavlatos, S.; Tseleni-Balafouta, S.; Giannatou, E.; Mallas, E.; Safioleas, M. 2005: Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues Hepato-Gastroenterology 52(63): 731-741
Cremonesi, M.; Ferrari, M.; Di Dia, A.; Botta, F.; De Cicco, C.; Bodei, L.; Paganelli, G. 2011: Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 55(2): 155-167
Panigone, S.; Nunn, A.D. 2006: Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 50(4): 310-321
Gut, P.ł; Ruchała, M. 2019: Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues Neuro Endocrinology Letters 40(7-8): 315-318
Limouris, G.S.; Rassidakis, A.; Kondi-Paphiti, A.; Triantafyllou, N.; Manetou, A.; Giannakopoulos, V.; Toubanakis, N.; Psyhojios, I.; Stavraka, A.; Vlahos, L. 1997: Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide Anticancer Research 17(3b): 1593-1597
Vainas, I.; Koussis, C.; Pazaitou-Panayiotou, K.; Drimonitis, A.; Chrisoulidou, A.; Iakovou, I.; Boudina, M.; Kaprara, A.; Maladaki, A. 2004: Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma Journal of Experimental and Clinical Cancer Research: Cr 23(4): 549-559
Koc, E.U.; Ozgur, T.; Yerci, O.; Gurel, S. 2013: Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma Hepato-Gastroenterology 60(127): 1693-1697
Kisker, O.; Bartsch, D.; Weinel, R.J.; Joseph, K.; Welcke, U.H.; Zaraca, F.; Rothmund, M. 1997: The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors Journal of the American College of Surgeons 184(5): 487-492
Kälkner, K.M.; Janson, E.T.; Nilsson, S.; Carlsson, S.; Oberg, K.; Westlin, J.E. 1995: Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers Cancer Research 55(23 Suppl): 5801s-5804s
Virgolini, I.; Traub, T.; Leimer, M.; Novotny, C.; Pangerl, T.; Ofluoglu, S.; Halvadjieva, E.; Smith-Jones, P.; Flores, J.; Li, S.R.; Angelberger, P.; Havlik, E.; Andreae, F.; Raderer, M.; Kurtaran, A.; Niederle, B.; Dudczak, R. 2000: New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 44(1): 50-58
O'Carroll, A.M.; Lolait, S.J.; König, M.; Mahan, L.C. 1993: Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin: 28 Molecular Pharmacology 44(6): 1278
Phan, A.T.; Yao, J.C. 2008: Neuroendocrine tumors: novel approaches in the age of targeted therapy Oncology 22(14): 1617-1623; Discussion: 1623-1624, 1629
Gorden, P.; Comi, R.J.; Maton, P.N.; Go, V.L. 1989: NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut Annals of Internal Medicine 110(1): 35-50